Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
36. |
ECCT/24/03/03 | DoxyDOT Study Weekly doxycycline DOT for STI prevention among cisgender women taking HIV PrEP in Kisumu, Kenya |
Principal Investigator(s) 1. Elizabeth Anne Bukusi Site(s) in Kenya KEMRI CMR RCTP |
View |
37. |
ECCT/24/03/02 | PEARL RSVt Vaccine Study Phase III, randomized, observer-blind, placebo-controlled, multi-center, multinational study to evaluate the efficacy, immunogenicity, and safety of a Respiratory Syncytial Virus vaccine in infants and toddlers (PEARL |
Principal Investigator(s) 1. Dr. Janet Nyawira Oyieko Site(s) in Kenya 1. KEMRI CCR – Butere Clinical Research Centre (Kakamega county) |
View |
38. |
ECCT/24/03/01 | RAD-TB A Phase 2 Randomized, Adaptive, Dose-Ranging, Open-Label Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis |
Principal Investigator(s) 1. Dr Josphat Kosgei Kosgei Site(s) in Kenya Kenya medical research institute/ Walter Reed program KERICHO |
View |
39. |
ECCT/24/02/10 | IMBrave A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING ATEZOLIZUMAB AND BEVACIZUMAB, WITH OR WITHOUT TIRAGOLUMAB, IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA |
Principal Investigator(s) 1. Dr. Pauline Njoki Njiraini Site(s) in Kenya University of Nairobi -Institute of Tropical and Infectious Diseases |
View |
40. |
ECCT/24/02/09 | pionERA This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib), in participants with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer who have developed resistance to adjuvant endocrine therapy. |
Principal Investigator(s) 1. Dr Sitna Ali Site(s) in Kenya University of Nairobi -Institute of Tropical and Infectious Diseases |
View |